14-day Premium Trial Subscription Try For FreeTry Free

Range Low Price High Price Comment
30 days $190.22 $268.22 Thursday, 25th Apr 2024 MDGL stock ended at $194.38. This is 5.02% less than the trading day before Wednesday, 24th Apr 2024. During the day the stock fluctuated 5.47% from a day low at $190.22 to a day high of $200.63.
90 days $168.25 $299.98
52 weeks $119.76 $322.67

Historical Madrigal Pharmaceuticals, Inc. prices

Date Open High Low Close Volume
Apr 25, 2024 $200.63 $200.63 $190.22 $194.38 699 326
Apr 24, 2024 $218.08 $219.99 $204.16 $204.65 575 000
Apr 23, 2024 $212.82 $225.66 $210.10 $218.38 409 527
Apr 22, 2024 $205.19 $217.14 $197.86 $213.49 717 263
Apr 19, 2024 $221.85 $224.68 $206.03 $212.04 620 067
Apr 18, 2024 $224.82 $227.31 $220.74 $222.26 268 684
Apr 17, 2024 $235.91 $235.91 $224.39 $228.34 241 128
Apr 16, 2024 $228.03 $235.92 $222.90 $232.98 337 667
Apr 15, 2024 $237.00 $242.82 $229.01 $231.37 322 852
Apr 12, 2024 $243.09 $245.36 $236.49 $236.59 294 751
Apr 11, 2024 $245.08 $248.63 $243.25 $245.27 189 457
Apr 10, 2024 $242.00 $246.23 $241.48 $244.67 226 067
Apr 09, 2024 $251.41 $253.17 $244.02 $249.34 226 902
Apr 08, 2024 $245.84 $248.82 $242.20 $248.64 226 743
Apr 05, 2024 $240.11 $246.17 $238.27 $243.04 294 541
Apr 04, 2024 $244.39 $248.42 $240.33 $241.46 384 864
Apr 03, 2024 $242.00 $247.33 $241.13 $245.23 455 747
Apr 02, 2024 $248.72 $250.94 $241.52 $244.50 593 191
Apr 01, 2024 $267.28 $267.28 $255.00 $255.74 546 667
Mar 28, 2024 $258.54 $268.22 $254.87 $267.04 435 650
Mar 27, 2024 $250.00 $259.53 $244.85 $258.81 398 840
Mar 26, 2024 $247.00 $251.99 $246.61 $247.62 229 626
Mar 25, 2024 $248.85 $257.48 $246.54 $247.62 346 116
Mar 22, 2024 $258.49 $258.52 $242.38 $248.20 523 911
Mar 21, 2024 $261.64 $265.27 $251.79 $255.27 368 265
Click to get the best stock tips daily for free!

About Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals. Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745,... MDGL Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT